BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Credit Suisse Upgrades Lupin to Outperform
Credit Suisse has upgraded Lupin to 'outperform' for target price of Rs 2,250 per share. Credit Suisse says that Fortamet's price increase is sustainable and upside potential from diabetes drugs is not priced in yet. Credit Suisse adds that FDA overhang on Goa facility has reduced and it has increased FY17/18 estimated EPS for Lupin by 18 per cent.